Optimal Blood-Brain Barrier Shuttle
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 16 4889
(44) Ottaviani, G.; Martel, S.; Carrupt, P. Parallel Artificial Membrane
Permeability Assay: A New Membrane for the Fast Prediction of
Passive Human Skin Permeability. J. Med. Chem. 2006, 49, 3948–
3954.
(45) Ottaviani, G.; Martel, S.; Carrupt, P. In Silico and in Vitro Filters for
the Fast Estimation of Skin Permeation and Distribution of New
Chemical Entities. J. Med. Chem. 2007, 50, 742–748.
(46) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High
Throughput Artificial Membrane Permeability Assay for Blood-Brain
Barrier. Eur. J. Med. Chem. 2003, 38, 223–232.
(47) Carrara, S.; Reali, V.; Misiano, P.; Dondio, G.; Bigogno, C. Evaluation
of in Vitro Brain Penetration: Optimized PAMPA and MDCKII-MDR1
Assay Comparison. Int. J. Pharm. 2007, 345, 125–133.
(48) Avdeef, A. Absorption and Drug DeVelopment; Wiley-Interscience:
New York, 2003; pp 226-227.
(49) Avdeef, A.; Strafford, M.; Block, E.; Balogh, M. P.; Chambliss, W.;
Khan, I. Drug Absorption in Vitro Model: Filter-Immobilized Artificial
Membranes 2. Studies of the Permeability Properties of Lactones in
Piper Methysticum Forst. Eur. J. Pharm. Sci. 2001, 14, 271–280.
(50) Youdim, K. A.; Avdeef, A.; Abbott, N. J. In Vitro Trans-Monolayer
Permeability Calculations: Often Forgotten Assumptions. Drug Dis-
coVery Today 2003, 8, 997–1003.
(51) Kansy, M.; Avdeef, A.; Fischer, H. Advances in Screening for
Membrane Permeability: High-Resolution PAMPA for Medicinal
Chemists. Drug DiscoVery Today: Technol. 2004, 1, 349–355.
(52) Liu, H.; Sabus, C.; Caretr, G. T.; Du, C.; Avdeef, A.; Tischler, M. In
Vitro Permeability of Poorly Aqueous Soluble Compounds Using
Different Solubilizers in the PAMPA Assay with Liquid Chromatog-
raphy/Mass Spectrometry Detection. Pharm. Res. 2003, 20, 1820–
1826.
(53) Sugano, K.; Hamada, H.; Machida, M.; Ushio, H.; Sitoh, K.; Terada,
K. Optimized Conditions of Bio-Mimetic Artificial Membrane Per-
meation Assay. Int. J. Pharm. 2003, 228, 181–188.
(54) Puell, J. A.; Tsinman, O.; Avdeef, A. Acid-Base Cosolvent Method
for Determining Aqueous Permeability of Amiodarone, Itraconazole,
Tamoxifen, Terfenadine and Other Very Insoluble Molecules. Chem.
Pharm. Bull. 2004, 52, 561–565.
(55) Ong, S.; Liu, H.; Qiu, X.; Bhat, G.; Pidgeon, C. Membrane Partition
Coefficients Chromatographically Measured Using Immobilized Ar-
tificial Membrane Surfaces. Anal. Chem. 1995, 67, 755–762.
(56) Pidgeon, C.; Ong, S.; Liu, H.; Qiu, X.; Pidgeon, M.; Dantzing, A. H.;
Munroe, J.; Hornback, W. J.; Kasher, J. S.; Glunz, L.; Szczerba, T.
IAM Chromatography: An in Vitro Screen for Predicting Drug
Membrane Permeability. J. Med. Chem. 1995, 38, 590–594.
(57) Nasal, A.; Aznitowska, M.; Bucinski, A.; Kaliszan, R. Hydrophobicity
Parameter from High-Performance Liquid Chromatography on an
Immobilized Artificial Membrane Column and Its Relationship to
Bioactivity. J. Chromatogr., A 1995, 692, 83–89.
(58) Yoon, C. H.; Shin, B. S.; Chang, H. S.; Kwon, L. S.; Kim, H. Y.;
Yoo, S. E.; Yoo, S. D. Rapid Screening of Drug Absorption Potential
Using the Immobilized Artificial Membrane Phosphatidylcholine
Column and Molar Volume. Chromatographia 2004, 60, 399–404.
(59) Yoon, C. H.; Kim, S. J.; Shin, B. S.; Lee, K. C.; Yoo, S. D. Rapid
Screening of Blood-Brain Barrier Penetration of Drugs Using the
Immobilized Artificial Membrane Phosphatidylcholine Column Chro-
matography. J. Biomol. Screening 2006, 11, 13–20.
(60) Reichel, A.; Begley, D. J. Potential of Immobilized Artificial
Membranes for Predicting Drug Penetration across the Blood-Brain
Barrier. Pharm. Res. 1998, 15, 1270–1274.
(65) Janecka, A.; Kruszynski, R.; Fichna, J.; Kosson, P.; Janecki, T.
Enzymatic Degradation Studies of Endomorphin-2 and Its Analogs
Containing N-Methylated Amino Acids. Peptides 2006, 27, 131–135.
(66) Marschu¨tz, M. K.; Zauner, W.; Mattner, F.; Otava, A.; Buschle, M.;
Bernkop-Schnu¨rch, A. Improvement of the Enzymatic Stability of a
Cytotoxic T-Lymphocyte-Epitope Model Peptide for Its Oral Admin-
istration. Peptides 2002, 23, 1727–1733.
(67) Tugyi, T.; Uray, K.; Ivan, D.; Fellinger, E.; Perkins, A.; Hudecz, F.
Partial D-Amino Acid Substitution: Improved Enzymatic Stability and
Preserved Ab Recognition of a MUC2 Epitope Peptide. Proc. Natl.
Acad. Sci. U.S.A. 2005, 11, 413–418.
(68) Rennert, R.; Wespe, C.; Beck-Sickinger, A. G.; Neundorf, I. Develop-
ing Novel hCT Derived Cell-Penetrating Peptides with Improved
Metabolic Stability. Biochim. Biophys. Acta 2006, 1758, 347–354.
(69) Neugebauer, W.; Blais, P. A.; Halle´, S.; Filteau, C.; Regoli, D.; Gobeil,
F., Jr. Kinin B1 Receptor Antagonists with Multi-Enzymatic Resistance
Properties. Can. J. Physiol. Pharmacol. 2002, 80, 287–292.
(70) Oh, J. E.; Lee, K. H. Synthesis of Novel Unnatural Amino Acid as a
Building Block and Its Incorporation into an Antimicrobial Peptide.
Bioorg. Med. Chem. 1999, 7, 2985–2990.
(71) Disney, M. D.; Hook, D. F.; Namoto, K.; Seeberger, P. H.; Seebach,
D. N-Linked Glycosylated ꢀ-Peptides Are Resistant to Degradation
by Glycoamidase A. Chem. BiodiVersity 2005, 2, 1624–1634.
(72) Tugyi, R.; Mezo¨, G.; Fellinger, E.; Andreu, D.; Hudecz, F. The Effect
of Cyclization on the Enzymatic Degradation of Herpes Simplex Virus
Glycoprotein D Derived Epitope Peptide. J. Pept. Sci. 2005, 11, 642–
649.
(73) Powell, M. F.; Stewart, T.; Otvos Jr., L.; Urge, L.; Gaeta, F. C. A.;
Sette, A.; Arrhenius, T.; Thomson, D.; Soda, K.; Colon, S. M. Peptide
Stability in Drug Development. II. Effect of Single Amino Acid
Substitution and Glycosylation on Peptide Reactivity in Human Serum.
Pharm. Res. 1993, 10, 1268–1273.
(74) Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan Peptides: The
Penetratin System for Intracellular Delivery. Trends Cell Biol. 1998,
8, 84–87.
(75) Pardridge, W. M. Blood-Brain Barrier Drug Targeting: The Future
of Brain Drug Development. Mol. InterVentions 2003, 3, 90–105.
(76) Witt, K. A.; Davis, T. P. CNS Drug Delivery: Opioid Peptides and
the Blood-Brain Barrier. AAPS J. 2006, 8, E76-E88.
(77) Deeken, J. F.; Loscher, W. Blood-Brain Barrier and Cancer:
Transporters, Treatment, and Trojan Horses. Clin. Cancer Res. 2007,
13, 1663–1674.
(78) McDowell, F. H.; Lee, J. E. L-Dopa in Parkinson’s Disease. West.
J. Med. 1970, 113, 44–46.
(79) Hawkins, R. A.; Mokashi, A.; Simpson, I. A. An Active Transport
System in the Blood-Brain Barrier May Reduce Levodopa Avail-
ability. Exp. Neurol. 2005, 195, 267–271.
(80) Pinnen, F.; Cacciatore, I.; Cornacchia, C.; Sozio, P.; Iannitelli, A.;
Costa, M.; Pecci, L.; Nasuti, C.; Cantalamessa, F.; Di Stefano, A.
Synthesis and Study of L-Dopa-Glutathione Codrugs as New Anti-
Parkinson Agents with Free Radical Scavenging Properties. J. Med.
Chem. 2007, 50, 2506–2515.
(81) Di Stefano, A.; Carafa, M.; Sozioa, P.; Pinnena, F.; Braghirolia, D.;
Orlandoa, G.; Cannazzab, G.; Ricciutellic, M.; Marianeccid, C.;
Santucci, E. Evaluation of Rat Striatal L-Dopa and DA Concentration
after Intraperitoneal Administration of L-Dopa Prodrugs in Liposomal
Formulations. J. Controlled Release 2004, 99, 293–300.
(82) Cannazza, G.; Di Stefano, A.; Mosciatti, B.; Braghiroli, D.; Baraldi,
M.; Pinnen, F.; Sozio, P.; Benatti, C.; Parenti, C. Detection of
Levodopa, Dopamine and Its Metabolites in Rat Striatum Dialysates
Following Peripheral Administration of L-Dopa Prodrugs by Means
of HPLC-EC. J. Pharm. Biomed. Anal. 2005, 36, 1079–1084.
(83) Fischera, H.; Kansya, M.; Avdeef, A.; Senner, F. Permeation of
Permanently Positive Charged Molecules through Artificial
MembranessInfluence of Physico-Chemical Properties. Eur. J. Pharm.
Sci. 2007, 31, 32–42.
(84) Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color Test
for Detection of Free Terminal Amino Groups in the Solid-Phase
Synthesis of Peptides. Anal. Biochem. 1970, 34, 595–598.
(85) Madder, A.; Farcy, N.; Hosten, N. G. C.; De Muynck, H.; De Clercq,
P. J.; Barry, J.; Davis, A. P. A Novel Sensitive Colorimetric Assay
for Visual Detection of Solid-Phase Bound Amines. Eur. J. Org. Chem.
1999, 2787–2791.
(61) Taillardat-Bertschinger, A.; Marca Martinet, C. A.; Carrupt, P.; Reist,
M.; Caron, G.; Fruttero, R.; Testa, B. Molecular Factors Influencing
Retention on Immobilized Artificial Membranes (IAM) Compared to
Partitioning in Liposomes and n-Octanol. Pharm. Res. 2002, 19, 729–
737.
(62) Austin, R. P.; Davis, A. M.; Manners, C. N. Partitioning of Ionizing
Molecules between Aqueous Buffers and Phospholipid Vesicles.
J. Pharm. Sci. 1995, 84, 1180–1183.
(63) Ballet, S.; Misicka, A.; Kosson, P.; Lemieux, C.; Chung, N. N.;
Schiller, P. W.; Lipkowski, A. W.; Tourwe, D. Blood-Brain Barrier
Penetration by Two Dermorphin Tetrapeptide Analogues: Role of
Lipophilicity vs Structural Flexibility. J. Med. Chem. 2008, 51, 2571–
2574.
(64) Boguslavsky, V.; Hruby, V. J.; O’Brien, D. F.; Misicka, A.; Lipkowski,
A. W. Effect of Peptide Conformation on Membrane Permeability. J.
Pept. Res. 2003, 61, 287–297.
(86) Sieber, P. A New Acid-Labile Anchor Group for the Solid-Phase
Synthesis of C-Terminal Peptide Amides by the Fmoc Method.
Tetrahedron Lett. 1987, 28, 2107–2110.
JM800156Z